eprintid: 18666
rev_number: 2
eprint_status: archive
userid: 1
dir: disk0/00/01/86/66
datestamp: 2024-06-04 14:11:01
lastmod: 2024-06-04 14:11:01
status_changed: 2024-06-04 14:03:49
type: article
metadata_visibility: show
creators_name: Uddin, S.
creators_name: Islam, M.R.
creators_name: Moshikur, R.M.
creators_name: Wakabayashi, R.
creators_name: Moniruzzaman, M.
creators_name: Goto, M.
title: Modification with Conventional Surfactants to Improve a Lipid-Based Ionic-Liquid-Associated Transcutaneous Anticancer Vaccine
ispublished: pub
keywords: antigen; immunological adjuvant; lipid; surfactant; vaccine, animal; C57BL mouse; cutaneous drug administration; drug delivery system; mouse, Adjuvants, Immunologic; Administration, Cutaneous; Animals; Antigens; Drug Delivery Systems; Lipids; Mice; Mice, Inbred C57BL; Surface-Active Agents; Vaccines
note: cited By 3
abstract: Transcutaneous vaccination is one of the successful, affordable, and patient-friendly advanced immunization approaches because of the presence of multiple immune-responsive cell types in the skin. However, in the absence of a preferable facilitator, the skin�s outer layer is a strong impediment to delivering biologically active foreign particles. Lipid-based biocompatible ionic-liquid-mediated nanodrug carriers represent an expedient and distinct strategy to permit transdermal drug delivery; with acceptable surfactants, the performance of drug formulations might be further enhanced. For this purpose, we formulated a lipid-based nanovaccine using a conventional (cationic/anionic/nonionic) surfactant loaded with an antigenic protein and immunomodulator in its core to promote drug delivery by penetrating the skin and boosting drug delivery and immunogenic cell activity. In a follow-up investigation, a freeze�dry emulsification process was used to prepare the nanovaccine, and its transdermal delivery, pharmacokinetic parameters, and ability to activate autoimmune cells in the tumor microenvironment were studied in a tumor-budding C57BL/6N mouse model. These analyses were performed using ELISA, nuclei and HE staining, flow cytometry, and other biological techniques. The immunomodulator-containing nanovaccine significantly (p < 0.001) increased transdermal drug delivery and anticancer immune responses (IgG, IgG1, IgG2, CD8+, CD207+, and CD103+ expression) without causing cellular or biological toxicity. Using a nanovaccination approach, it is possible to create a more targeted and efficient delivery system for cancer antigens, thereby stimulating a stronger immune response compared with conventional aqueous formulations. This might lead to more effective therapeutic and preventative outcomes for patients with cancer. © 2023 by the authors.
date: 2023
official_url: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85152322299&doi=10.3390%2fmolecules28072969&partnerID=40&md5=3fe66001e06bbce0fdbceff21aa43182
id_number: 10.3390/molecules28072969
full_text_status: none
publication: Molecules
volume: 28
number: 7
refereed: TRUE
citation:   Uddin, S. and Islam, M.R. and Moshikur, R.M. and Wakabayashi, R. and Moniruzzaman, M. and Goto, M.  (2023) Modification with Conventional Surfactants to Improve a Lipid-Based Ionic-Liquid-Associated Transcutaneous Anticancer Vaccine.  Molecules, 28 (7).